Drug intelligence / Profile preview

ECC4703

Development stage: Phase 2
Lead developer: Eccogene
Modality: Small Molecules
Administration: Oral

Overview

ECC4703 is a novel, orally administered small molecule drug under development by Eccogene for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH). It acts as a highly selective, liver-targeting full agonist of thyroid hormone receptor beta (THRβ), showing desired potency and selectivity in preclinical studies. ECC4703 has demonstrated clear target engagement with significant reductions in LDL cholesterol and other atherogenic lipids in early clinical trials. The drug is currently in Phase 1 clinical development for both NASH/MASH and dyslipidemia.

Other names: ECC4703 F0 formulationECC-4703 F0 formulationECC 4703 F0 formulation

Targets

THRB (Thyroid hormone receptor beta)

Beyond the preview

Go deeper on ECC4703.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ECC4703.

Explore the full profile